Note: This document is an English translation of a statement written originally in Japanese. The Japanese original should be considered as the primary version.

November 4, 2026

Company name: Zeria Pharmaceutical Co., Ltd.
Name of representative: Mitsuhiro Ibe,
Representative Director, President
(Securities code: 4559; Prime Market, TSE)
Inquiries: Koichi Tamura
Director, Public Relations Division
(Telephone: +81-3-3661-1039)

Notice Regarding Revision to Year-End Dividend Forecast (Increase)

Zeria Pharmaceutical Co., Ltd. (the"Company") hereby announces that its Board of Directors has resolved at a meeting held today to revise the year-end dividend forecast for the fiscal year ending March 31, 2027, as follows.

1. Reason for the Revision to the Year-End Dividend Forecast

The Company regards the return of profits to shareholders as one of its highest management priorities, and its basic profit distribution policy is to pay stable and continuous dividends.

Taking into account the Company's performance up to the second quarter and other factors, the Company has decided to increase the dividend by 1 yen from the previous forecast of 25.00 yen to 26.00 yen per share. As a result, the annual dividend forecast will be 51.00 yen per share.

2. Details of the Revision

	Dividend per share		
Record date	Second quarter-end	Fiscal-year-end	Total
Previous forecast (May 8, 2026)	25.00 yen	25.00 yen	50.00 yen
Revised forecast	—	26.00 yen	51.00 yen
Actual results for the current fiscal year	25.00 yen	—	—
Actual results for the previous fiscal year (Fiscal year ended March 31, 2026)	24.00 yen	25.00 yen	49.00 yen